Podium to Practice: ASH® 2025 – LEUKEMIA: KOMET-007
OR
[magic_login_form]
Explore more from your favourite experts – click their name to access their entire library of content.
Chair
Speakers
Studies / Trials Discussed
ID 766 – Ziftomenib in combination with venetoclax and azacitidine in newly diagnosed NPM1-m acute myeloid leukemia: Phase 1b results from KOMET-007
This program has been made possible through unrestricted support from Astellas and Daiichi Sankyo.
Studies/trials discussed:
ID 766 – Ziftomenib in combination with venetoclax and azacitidine in newly diagnosed NPM1-m acute myeloid leukemia: Phase 1b results from KOMET-007
Login to view content
PLease Enter Your Email to view Content
Pre-Video Survey
By continuing to watch the video, you consent to receiving a post-view survey by email.